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Abstract 24 
 25 
Staphylococcus aureus is the most prevalent organism isolated from the airways of people 26 
with cystic fibrosis (CF), predominantly early in life. Yet its role in the pathology of lung 27 
disease is poorly understood. In mice, and many experiments using cell lines, the 28 
bacterium invades cells or interstitium, and forms abscesses. This is at odds with the 29 
limited available clinical data: interstitial bacteria are rare in CF biopsies and abscesses 30 
are highly unusual. Bacteria instead appear to localise in mucus plugs in the lumens of 31 
bronchioles. We show that, in an established ex vivo model of CF infection comprising 32 
porcine bronchiolar tissue and synthetic mucus, S. aureus demonstrates clinically 33 
significant characteristics including colonisation of the airway lumen, with preferential 34 
localisation as multicellular aggregates in mucus, initiation of a small colony variant 35 
phenotype and increased antibiotic tolerance of tissue-associated aggregates. Tissue 36 
invasion and abscesses were not observed. Our results may inform ongoing debates 37 
relating to clinical responses to S. aureus in people with CF. 38 
 39 
Impact Statement  40 
Chronic bacterial infection is one of the main causes of declining lung function and 41 
morbidity in people with cystic fibrosis (CF). Staphylococcus aureus is the most 42 
prevalent organism isolated from airways of infants with CF. Yet its overall role in the 43 
pathogenesis of pulmonary disease is poorly understood. More accurate, high 44 
throughput models of CF lung infection are necessary to explore the interactions 45 
between S. aureus and host in this context. In vitro studies cannot accurately replicate 46 
chronic disease characteristics, such as presence of small colony variants, and animal 47 
models also do not represent features of clinical disease. Mice, in particular, are not 48 
readily colonised by S. aureus and when infection is established it leads to the 49 
formation of abscess, a phenomenon not observed in the human CF lung. Here we 50 
show an existing ex vivo pig lung model of CF infection supports growth of S. aureus 51 
and that S. aureus demonstrates clinically significant characteristics including 52 
appearance of small colony variants, increased antibiotic tolerance and preferential 53 
growth as aggregates in mucus. 54 
 55 
Data summary  56 
The authors confirm all supporting data, code and protocols have been provided within 57 
the article or through supplementary data files. 58 
 59 
Introduction  60 
 61 
Staphylococcus aureus (S. aureus) is currently the most prevalent pathogen isolated 62 
from the airways of people with cystic fibrosis (CF) (1).  Historically, it is has been 63 
associated predominantly with paediatric pulmonary infection (2) yet most recent data 64 
shows that ~50% of even the oldest patients are now colonised (3). The presence of 65 
S. aureus in the respiratory tract varies considerably geographically and over time, 66 
and although prevalence appears to decrease with age (4) MRSA is most prevalent 67 
between 10-30 year olds(3). Determining the difference between colonisation and 68 
infection is both important and difficult. Nasal carriage of S. aureus among children 69 
with cystic fibrosis is common: Stone et al. (5) reported that 52.4% of the infants they 70 
studied harboured the organism. However, relatively high carriage rates in healthy 71 
children have also been recorded (6). Further, expectorate is difficult to collect from 72 
infants, so samples are usually collected by oropharyngeal swab, but presence of 73 
organisms in the upper respiratory tract is not always indicative of lower airway 74 
infection (7, 8). 75 
 76 
Moreover, the association of S. aureus with progressive lung disease – as measured 77 
by worsening lung function and the development of subsequent infection by the 78 
chronic CF pathogen Pseudomonas aeruginosa – is unclear (9).  S. aureus is able to 79 
rapidly adapt to and persist in the CF lung environment (10), and worsening lung 80 
condition has been associated with the formation of  S. aureus small colony variants 81 
(SCVs) (11). SCVs are known to remain in the lung longer than wild type (WT) 82 
bacterial cells (12) and demonstrate increased antimicrobial resistance (13).  In 83 
studies of bronchoalveolar lavage (BAL) fluid from children aged 0-7 years, both 84 
Gangell et al. and Sagel et al. (14, 15) found that positive S. aureus culture was linked 85 
to a higher degree of airway inflammation, as measured by increased neutrophil count 86 
and IL-8. In another study, lung damage (bronchiectasis) in early CF was recorded by 87 
CT scan and S. aureus was the most commonly isolated organism (16). Conversely, 88 
in adult CF patients, S. aureus infections, in the absence of P. aeruginosa, are a 89 
marker of milder disease (1).  There is also an indication that methicillin sensitive S. 90 
aureus may inhibit P. aeruginosa, thus delaying lung disease progression (17). The 91 
evidence that early S. aureus infection worsens prognosis for CF patients remains 92 
conflicting and warrants further study (3)(18).  93 
 94 
The lack of understanding regarding the role of S. aureus in the development of lung 95 
disease in CF has led to debate over the use of anti-staphylococcal prophylaxis early 96 
in life. Studies by Ratjen et al. and Stutman et al. (19, 20) linked the use of broad-97 
spectrum antibiotics to an increase in P. aeruginosa isolation. However, a recent 98 
Cochrane review (21) showed no effect of anti-staphylococcal prophylaxis on P. 99 
aeruginosa colonisation at 3-4 years. There was a suggested trend towards higher 100 
rates of P. aeruginosa at 4-6 years but as the studies reviewed did not last more than 101 
six years, conclusions about the long-term effects of prophylaxis could not be drawn. 102 
A pragmatic randomized controlled trial is currently in progress 103 
(http://www.cfstart.org.uk). 104 
 105 
In addition to the lack of clarity over the clinical consequences of S. aureus colonisation, 106 
there is also a gap in our mechanistic understanding of the microbiology of S. aureus in 107 
CF. The interaction of S. aureus with the pulmonary airway in CF, and its subsequent role 108 
in pathogenesis, is not clearly documented. CF epithelial cells have been shown to have 109 
an increased abundance of aGM1, a receptor that binds S. aureus and P. aeruginosa, 110 
compared with wild-type epithelia (22), and an in vitro study by Schwab et al. 111 
demonstrated that bacterial adherence to a bronchial epithelial cell line was significantly 112 
greater for CF S. aureus isolates than non-CF (23). McKenney et al. also show aggregates 113 
of S. aureus are visible on the surfaces of bronchial sections from children with CF (24). 114 
Yet, the only other study we found with direct evidence of S. aureus infection in human 115 
biopsy specimens, demonstrated that S. aureus did not adhere to the airway epithelium 116 
but was found aggregating within the mucus (25). Furthermore, these authors cited 117 
several studies reporting an ability of S. aureus to bind mucins (26, 27). It is obvious that 118 
better understanding of just how S. aureus colonizes the airway in CF is required, as are 119 
unambiguous data on the underlying mechanisms of pathogenesis and virulence, and the 120 
influence of S. aureus on subsequent infection by other microorganisms.  121 
 122 
Mice are the most commonly used animal model of pulmonary infection in CF. Mouse 123 
models have been used to identify virulence-related genes in pathogens and to test 124 
novel therapeutic agents aimed at reducing inflammation or infection (28).  However, 125 
mouse models present a number of challenges. In particular, mice do not develop 126 
spontaneous P. aeruginosa endobronchial infection, suppurative lung disease and 127 
mucus plugging of the airways, that are fundamental characteristics of human CF 128 
progression (29). S. aureus does not appear to readily colonize the airways of mice or 129 
produce an inflammatory response, even when clinical strains are used, in the 130 
presence of mucus (30). Furthermore, S. aureus forms severe abscess-like lesions in 131 
the mouse lung (31). When lung abscess does occur in humans, S. aureus is the most 132 
commonly isolated organism (32). However, lung abscess is rare in children (33) and 133 
even more so in people with CF: since the advent of neonatal screening and survival 134 
past infancy, abscesses are almost never observed in the CF population (34-36). 135 
  136 
We previously developed a clinically relevant, high throughput model of chronic bacterial 137 
infection in CF.  By combining sections of porcine bronchiole (obtained post-slaughter 138 
from a commercial abattoir) with culture medium which mimics CF sputum (artificial 139 
sputum medium, ASM (37)) we have shown that we can study another key CF pathogen, 140 
P. aeruginosa, in a physicochemical environment similar to that present in vivo (38-40). 141 
The use of CF-like growth medium combined with animal tissue with a greater structural, 142 
chemical and immunological similarity to human lung (41) means that our model is likely 143 
to facilitate a more human-like pathology of S. aureus than that observed in mouse models 144 
or in vitro studies. Using clinical reference strains and CF isolates of S. aureus, we can 145 
now demonstrate that in a CF-like environment, S. aureus shows non-invasive pathology. 146 
Bacteria grow as aggregates associated with the surface of bronchioles and in the 147 
surrounding artificial sputum, without the formation of abscesses or other significant 148 
ultrastructural changes to tissue. In fact, we report a potential preference for aggregation 149 
in the surrounding mucus rather than growth associated with the bronchiolar surface. We 150 
also report the appearance of sub-populations of SCVs. Our work is consistent with S. 151 
aureus adopting a “persister” rather than “invader” strategy in CF. This stands in marked 152 
contrast to the pathology of this species in mouse and cell culture infection models, and 153 
underlines the importance of selecting models that reflect host-pathogen interactions 154 
more closely, in order to reliably study the role of specific bacteria in clinical disease 155 
progression. A better understanding of S. aureus pathology in the highly idiosyncratic 156 
environment of the CF lungs will inform optimised clinical responses to positive S. aureus 157 
cultures. 158 
 159 
Materials and Methods  160 
 161 
Bacterial strains. USA300 Los Angeles County clone (JE2, BEI resources) was used 162 
as an example of a well-documented clinical strain. 18 S. aureus stains isolated from 163 
9 people with CF at Hospital Universitari i Politecnic La Fe were included as exemplars 164 
of CF associated strains. The strains used in this work were extracted for diagnostic 165 
purposes and sent to the microbiology service for routine analysis. Once analyzed, 166 
and instead of being discarded as usual, the strains were grown in tryptic soy broth 167 
and kept in glycerin. We chose isolates that represented a range of patient clinical 168 
presentation and bacterial phenotypes (e.g. weak or strong biofilm formation as 169 
measured by in vitro attachment assays, and isolates from patients during periods of 170 
stable presentation and episodes of acute exacerbation) (See Table S1). 171 
 172 
Media and culture conditions for growth in the ex vivo pig lung (EVPL) model.  173 
For use in the lung model, bacterial stocks were grown overnight at 37 °C on lysogeny 174 
broth (LB) agar. Artificial sputum medium (ASM) was prepared according to Palmer et 175 
al. (37) with the modification that we removed glucose and supplemented with 20 176 
µg ml−1 ampicillin.  Our previous work suggested that glucose facilitated the growth of 177 
endogenous bacteria present in the lungs and that ampicillin helped to limit the growth 178 
of any resident bacteria in the lung that remained after sterilisation (38). We selected 179 
a concentration of ampicillin that provided the best possible coverage against 180 
endogenous populations but was sub-inhibitory for the S. aureus strains used 181 
(confirmed by standard MIC testing at the time of collection).  182 
 183 
The EVPL model was adapted from our group’s previous work (38, 39), which in turn 184 
built on prior use of pig lungs for non-CF studies (42). Briefly, lungs were collected 185 
from a local butcher (Steve Quigley and Sons, Cubbington, Warwickshire) as soon as 186 
possible following abattoir delivery, and processed immediately upon arrival at the 187 
laboratory. Previous antibiotic administration history of the pigs is not known, but use 188 
of antibiotics as growth promoters is banned in the EU, so use is restricted to 189 
prophylaxis and mass medication of herds only when infection is suspected. 190 
Approximately 5mm2 sections of bronchiolar tissue were dissected from the lung under 191 
sterile conditions. During dissection the sections were washed three times with a 1:1 192 
mix of RPMI 1640 and Dulbecco's modified Eagle medium (DMEM) (Sigma-Aldrich), 193 
supplemented with 50 µg ml−1 ampicillin, and then rinsed once in sterile ASM without 194 
ampicillin supplementation. Bronchiolar samples were transferred to a clean petri dish 195 
and sterilized under a UV lamp for 5 minutes. Previous work has shown that tissue 196 
damage as a result of UV sterilisation is minimal (not visible using light microscopy)  197 
(39). Samples were transferred to 24-well tissue culture plates: each well contained 198 
400 µl ASM supplemented with 0.8 % w/v agarose to form a soft pad. Tissues were 199 
inoculated with the appropriate strain of bacteria using a sterile hypodermic needle 200 
(29G). The tip of the needle was lightly touched to the surface of the chosen S. aureus 201 
colony, and then used to pierce the surface of bronchiolar tissue for inoculation. A 202 
sterile needle was used for mock infection in uninfected controls.  500 µl of ASM + 20 203 
µg ml−1 ampicillin was added to each well and the plate was sealed with a Breath-204 
Easier membrane (Diversified Biotech). Plates were incubated at 37 °C for up to 7 205 
days and refreshed with 300 µl of ASM + 20 µg ml−1 ampicillin at 48 h. Following 206 
incubation, tissue was rinsed in 1 ml phosphate-buffered saline (PBS) to remove 207 
loosely adhering cells and processed for colony counts and microscopy.  208 
 209 
Bacterial load assay. Tissue samples used to assay total bacterial numbers in tissue-210 
associated biofilm were homogenised individually in 1ml PBS in reinforced metal bead 211 
tubes (Fisherbrand) using a FASTPREP 24 5G homogenizer (MP Biomedicals) for 40 212 
sec at 4.0m sec-1. Homogenates were serially diluted and aliquots were plated on LB 213 
and mannitol salt (MSA) agar (Oxoid, Thermo Scientific) to obtain single colonies. 214 
MSA agar is selective for Staphylococcus and was used to determine colony numbers 215 
of test strains and ensure that negative controls did not contain any S. aureus already 216 
resident in the lung tissue prior to experimentation. Non-selective LB agar was used 217 
to check for contamination or growth of endogenous populations. When bacterial load 218 
in ASM surrounding the lung tissue was measured, 300 µl of ASM was taken from 219 
each well at the same time as tissue processing and transferred to a sterile Eppendorf 220 
tube. Samples were vortexed, serially diluted and plated in the same way as tissue 221 
homogenate.  222 
LB plates were incubated aerobically at 37 °C for 18-24 h and MSA plates were 223 
incubated in at 37 °C 5% CO2 for 24 h and then for an additional 48 h at room 224 
temperature in ambient CO2 to allow visualisation of slow growing colonies. Total 225 
numbers of S. aureus recovered from the complete sample were calculated from 226 
tissue and ASM colony numbers combined. 227 
 228 
Microscopy. Replica 5mm2 bronchiolar tissue samples, dissected and inoculated as 229 
above, were preserved for hematoxylin and eosin staining. Samples were placed in 230 
individual tissue processing cassettes (Simport) and fixed overnight in 10% neutral 231 
buffered formalin (NBF) at approximately 20 times w/v. Longitudinal, step sections 232 
(100m) were prepared for histopathology by an external service (University of 233 
Manchester). If samples required storage before transport, they were placed in 70% 234 
ethanol and kept at 4°C for up to 7 days. Sections were transported in PBS with 235 
residual NBF. In addition, 10 µl samples were taken from the ASM surrounding lung 236 
tissue, diluted 1:10 in PBS and 5 µl drops prepared for gram stain.  237 
Microscopy was conducted with an Axio scope.A1 light microscope (Carl Zeiss) with 238 
AxioCam ERc5S digital camera and images processed in Zen Pro 2.1 Blue edition.   239 
 240 
Colony identification. Colonies that were able to grow on MSA plates and ferment 241 
mannitol (indicated by yellow pigmentation of colony and surrounding clear zone) were 242 
regarded as S. aureus. Colony morphology was recorded by digital photography. The 243 
identity of colonies that were weak fermenters or small in size was initially confirmed 244 
using hydrogen peroxide to test for the production of catalase and a staphylase assay 245 
(Oxoid). If SCVs were suspected, colonies were recovered by aerobic incubation 246 
overnight on Columbia Blood Agar and morphology was compared to the originally 247 
inoculated parent strain. PCR of large and small colonies from MSA plates was used 248 
to verify taxonomic identity. First, we performed colony PCR using Staphylococcus-249 
specific primers (43). Once genus was confirmed, amplification of the 16S-23S rRNA 250 
intergenic spacer region and Sanger sequencing was used to confirm that SCVs were 251 
S. aureus (primers 5’-TGCCAAGGCATCCACCG-3’ and 5’- 252 
GGCTGGATCACCTCCTT-3’). 253 
 254 
Determination of antibiotic susceptibility by microdilution. The minimium 255 
inhibitory concentration (MIC) of Flucloxacillin against a pair of representative MSSA 256 
isolates (FQ128 and FQ142) and the standard MSSA control strain, ATCC29213, was 257 
determined according to the british society of antimicrobial chemotherapy guidelines 258 
for microdilution (44) before examining antibiotic tolerance in the EVPL model. All 259 
isolates were from sputum samples collected from people with CF during stable 260 
presentation. All three strains demonstrated an MIC of <0.0625mg/l and were sensitive 261 
to flucloxacillin.  262 
 263 
Antibiotic tolerance in the EVPL model. Infected lung bronchioles incubated for 48 264 
h as described above.  At 48 h ‘pre-dose’ tissue samples were homogenized and 265 
assayed as above. Biological replicates (4 bronchiolar sections for each strain and 266 
condition) were challenged with antibiotic: tissue samples were washed in PBS then 267 
placed in a new 24 well plate on agar pads. 500µl ASM alone was added for controls 268 
and 500µl ASM + either 0.25mg/l or 5mg/l flucloxacillin for antibiotic tolerance test 269 
samples. Concentrations were calculated from the recorded broth MIC of < 0.0625mg/l 270 
for the strains tested and the clinical target pharmacokinetic (PK) parameters. The PK 271 
parameter for beta lactam efficacy is T>MIC with a target of 50% of dosing interval at 272 
a free plasma concentration 4-5 x MIC (45). 5mg/l was included to account for potential 273 
protein binding, which is 95% for Flucloxacillin (46). Plates were incubated at 37 °C. 274 
At 4 and 24 H post dose, treated tissues were washed in PBS to prevent any antibiotic 275 
carryover, and all samples homogenised and plated as described above. The bacterial 276 
loads in non-antibiotic and antibiotic treated tissues were compared.  277 
 278 
Statistical analysis All data were analysed using RStudio (Mac OS X 10.6+ version 279 
1.0.153) (RStudio, https://www.rstudio.com) using linear models followed by ANOVA 280 
and post-hoc Tukey HSD tests where appropriate, or using Kruskall-Wallis tests, as 281 
specified in the text.  282 
 283 
Results 284 
 285 
Clinical strains of Staphylococcus aureus are able to colonise EPVL. Data taken 286 
from preliminary experiments (Fig 1) showed that bacterial load (CFU) recovered at 287 
48 h was similar for a large range of S. aureus CF clinical isolates, and comparable to 288 
Los Angeles County clone of USA300, a methicillin resistant (MRSA) clinical isolate 289 
known to form biofilm (47). Table S1 shows details of CF isolates. Samples were taken 290 
from people presenting either with acute exacerbation or in a stable condition (defined 291 
as chronic isolates). Isolates were grouped randomly and tested on three separate 292 
occasions. In each case lung samples were dissected from a single lung. Differences 293 
in growth were distinguishable between strains (ANOVA. F2,40 = 1.9, p =0.02) but post 294 
hoc analyses showed no significant difference between any CF isolate and 295 
USA300LAC (see supplementary data). The median values for S. aureus load 296 
recovered at 48 h were 1.64105, 3.64105 and 6.1105 CFU respectively for lungs 1-297 
3. Growth on Staphylococcal selective media (MSA) was only observed on one of the 298 
uninfected controls (Fig 1, Panel A). 299 
 300 
S. aureus growth in association with bronchiolar tissue depends on strain and 301 
lung but trends are consistent overtime.  To verify the reproducibility of S. aureus 302 
numbers recovered from bronchiolar tissue and the ability to observe differences 303 
between strains, triplicate samples of USA300LAC and two clinical strains were 304 
inoculated into three further lungs taken from different pigs (Fig 2) and incubation was 305 
extended to 7 days. Clinical isolate FQ151 was compared with FQ184, these strains 306 
were chosen as an appropriate example pair as they were both isolated from patients 307 
with similar demographics, both MRSAs that form biofilm, and had both demonstrated 308 
comparable rates of recovery at 48 h from the same lung (Fig 1). However, FQ184 309 
was isolated during an acute disease exacerbation and FQ151 during stable 310 
presentation (representing chronic infection or colonisation) (Table S1). It was 311 
therefore hypothesised, that by comparing these two strains, differences between 312 
exacerbation-associated strains and those apparently persisting asymptomatically 313 
may be observed, and, if so, could be further investigated with a larger selection of 314 
paired isolates.   Figure 2 shows that USA300 was again able to establish in the lung 315 
and mean S. aureus load recovered at 48 h was 6.8106 CFU. Mean yields for clinical 316 
strains at 48 h were 3.8106 and 5.5105 CFU for FQ184 and FQ151, respectively. By 317 
7 days no colonies were recovered from tissue taken from one of the three lungs for 318 
either clinical strain, and counts for clinical strains in a second lung were below or 319 
close to the lower limit of detection. Average CFU counts at day 7 were 4.2103 for 320 
USA300, 7.9103 for FQ184 and 8.1103 for FQ151. The data were analysed by 321 
ANOVA to test for differences between strains, lungs and days, and interactions 322 
between day*lung and strain*lung. Total bacterial load was significantly different once 323 
again between strains (F2,40 = 12.0, p < 0.001) and between lungs (F2,40 = 6.03, p = 324 
0.005). There was a main effect of day (F1,40 = 155, p < 0.001) and the magnitude of 325 
the drop between 48 h and 7 days did not vary significantly between lungs (day*lung 326 
interaction F2,40 = 9.5, p = 0.110) or between strains (strain*day interaction F2,40 = 1.73, 327 
p = 0.190). Different lungs did, however, affect the growth of the strains differently 328 
(lung*strain interaction F4,40 = 2.62, p = 0.049).             329 
     330 
S. aureus is visible as aggregates at the airway-tissue interface but does not 331 
appear to invade tissue.  Monitoring bacterial load within the model by CFU count 332 
shows that the model can maintain a S. aureus population at 48 h. In addition, it was 333 
important to investigate whether the consistent decline in CFU counts by 7 days was 334 
due to the inability of the model to support S. aureus or whether adaptation of S. 335 
aureus within the model prevented sufficient monitoring, for example if cells were 336 
growing in strongly adherent biofilm that had not been washed off, or as SCV or 337 
persister cells that were difficult to recover on media.  Therefore, samples were 338 
histologically examined to gain a better understanding of growth characteristics in the 339 
model. Samples of the inoculated lung tissue (dissected from bronchi for original 340 
model) were washed in PBS and prepared for microscopy, by longitudinal, step section 341 
(100m), at 2 and 7 days post infection. Histopathological staining (Figure 3 and 4) 342 
showed bronchial mucosa, represented by mature cartilage. In infected samples there 343 
is clear evidence of polymorphs and organisms, including, predominantly gram 344 
positive bacilli. Polymorphs and organisms are largely absent from uninfected controls 345 
with the exception of a small number of rod shape organisms (fig 3b). Gram positive 346 
bacilli aggregate primarily at the tissue airway interface of infected lungs and their 347 
absence from the uninfected lung, (Figs 3a, 3b and 4a, 4b) strongly suggests that they 348 
are the S. aureus deliberately inoculated into test samples. Lung tissue remained 349 
largely intact across all tested isolates, even at 7 days. There was some disruption of 350 
tissue integrity at the surface, illustrated by the presence of fibrinous material 351 
(highlighted with *). None of the samples show any evidence of abscess, which would 352 
present as a clearly-defined, bordered structure. S. aureus is present only at the 353 
tissue-airway interface and does not appear to demonstrate tight association with 354 
tissue in the form of a mature biofilm, although more specific staining for biofilm would 355 
be required to confirm this. 356 
 357 
Evidence of other organisms in some samples, for example rod shaped cells in the 358 
tissue infected with FQ184 at 48 h (arrow, Fig 3f, 100x magnification),  is likely to be 359 
endogenous populations present prior to dissection (healthy lungs are not sterile) or 360 
contaminants not removed during sterilisation; they are also present in the uninfected 361 
control (arrow, Fig 3b). Interestingly, when other bacteria are present, there appear to 362 
be distinct ecological niches within the lung environment with gram positive bacilli 363 
clustered primarily at or near the surface, and rods present embedded within smooth 364 
muscle and connective tissue. This supports much of the current understanding of the 365 
structural architecture of polymicrobial communities and it would be useful to study 366 
this further especially as the presence of other bacteria may affect the ability of S. 367 
aureus to survive and adapt within the model.  By day 7, cells in clusters of FQ151 368 
were small and poorly stained, and thus difficult to image (Fig 4d). This may indicate 369 
the cells are no longer viable and explain the lack of colonies recovered on plates (Fig 370 
2). Although inconclusive, the images appear to suggest that there is still a presence 371 
of bacterial cocci in association with the lung tissue at 7 days post inoculation, despite 372 
poor recovery of colonies on selective media. It highlights that sputum sampling and 373 
colony count alone cannot reliably determine the presence of S. aureus populations 374 
that may be viable but non-culturable. It would be useful to further investigate, perhaps 375 
with the use of Staphylococcus aureus specific fluorescent probes or live dead staining 376 
in order to confirm the identity and viability of the cells.  377 
 378 
S. aureus aggregates in artificial sputum surrounding lung tissue. Initial 379 
experiments (Figs 1, 2) only recorded bacterial burden recovered from washed tissue 380 
pieces. The histology suggests at least some S. aureus may be tightly associated with 381 
the tissue in the model and not removed during homongenisation. In addition, there is 382 
evidence in the literature to suggest S. aureus may preferentially bind to mucus plugs 383 
in the airways of the CF lung, rather than associating with the tissue surface (25). Both 384 
are possible explanations as to why, despite presumably being adapted to the lung 385 
environment, CFU loads associated specifically with the bronchiolar tissue showed 386 
such a marked drop by day 7.  387 
 388 
A subset of clinical strains, two MRSA and two MSSA (methicillin sensitive) strains, 389 
were chosen to investigate growth in the surrounding ASM, and compared with 390 
USA300 (Fig 5). When bacteria were also recovered from the surrounding ASM and 391 
enumerated, the total CFU count from the sample (tissue plus surrounding ASM) was 392 
higher than the CFU count for tissue only (Fig 5a). Although ‘mucus plugs’ do not form 393 
in the model,  aggregates of S. aureus cells were visible in Gram stains of surrounding 394 
ASM at day 7 for all strains tested (Fig S5) and by day 7, a greater proportion of the 395 
total bacterial population was consistently found in the surrounding ASM than in tissue-396 
associated biofilm (Fig 5b). The four biofilm forming strains all showed a significant 397 
increase in the proportion of recoverable cells in the ASM between 48 h and day 7 as 398 
measured by the Kruskal Wallis Test (FQ128 𝜒1
2 = 7.44, FQ140  𝜒1
2 = 11, FQ151  𝜒1
2 = 399 
7.1, USA300 𝜒1
2 = 12.3; all p-values ≤ 0.008). FQ142 did not show a significant 400 
increase in ASM proportion between the two time points (Kruskal Wallis test, 𝜒1
2 = 1.2, 401 
p = 0.22). As FQ142 is not a biofilm former (Table S1), this is likely due to a higher 402 
proportion already in the ASM by 48 h. ASM is a minimal media and it is significant 403 
that there are viable cells are maintained in the ASM for 7 days with limited nutrient 404 
replenishment, suggesting the addition of lung tissue to the model is an important 405 
improvement.  406 
 407 
Tissue associated populations demonstrate phenotypes consistent with 408 
chronic infection. The data collected by cell enumeration (Figs 1, 2 and 5), for growth 409 
and localisation of S. aureus in the model, suggest the existence of subpopulations 410 
present during chronic infection. These likely comprise aggregates of cells in the 411 
mucus and a smaller percentage of tissue or biofilm associated cells, which may be 412 
slow growing SCVs or non-growing persisters.  If this is the case it would be consistent 413 
with hypotheses in the literature regarding S. aureus infection(48), and we would 414 
anticipate that there would be SCVs present in the model and the “persister” 415 
subpopulation would demonstrate increased antibiotic tolerance.  416 
 417 
Small colonies (<50% diameter of usual S. aureus colonies) were observed on MSA 418 
plates after incubation for at least 48 h in 5% CO2 at 37 °C for samples taken 7 days 419 
post inoculation. Example colonies were photographed (Fig S6) and some had weak 420 
catalase and coagulase results when tested, weak catalase is indicative of deficient 421 
heme production and associated with SCVs, as is weak coagulase. SCVs were 422 
confirmed as S. aureus spp. using genus-specific primers (STaG) (43) followed by 423 
sequencing of the 16s-23S intergenic region (Table S2).  424 
 425 
Antibiotic tolerance of tissue associated aggregates.  426 
 427 
Slow growing or biofilm bacterial populations may be tolerant to antibiotics and 428 
implicated in the persistence of chronic infection. Tolerance of tissue associated 429 
aggregates to flucloxacillin was assessed for a pair of clinically isolated MSSAs that 430 
were susceptible to flucloxacillin in a standard MIC microdilution and had the same 431 
MIC as the control strain ATCC29213 (<0.0625mg/l). They were isolated from people 432 
who presented asymptomatically (without exacerbation) (Table S1). Lung tissue was 433 
infected with S. aureus and incubated as described above.  At 48 h, antibiotic test 434 
samples were challenged with a single dose of either 0.25mg/l or 5mg/l (to account for 435 
potential protein binding) flucloxacillin; control samples were maintained in ASM alone. 436 
Tissue was processed at 4 and 24 h post dose and total S. aureus load recorded as 437 
before (Fig 6a). As in previous experiments, uninfected control tissues showed no 438 
growth on MSA plates. Clinically, bactericidal activity of an antibiotic is regarded as a 439 
reduction of 99.9% (>3 log10 decrease) in the CFU/ml of the original sample. The data 440 
presented in Fig 6b demonstrates that  a mean decrease of >3 log10  was only achieved 441 
against FQ142 when challenged with the higher concentration of 5mg/l flucloxacillin 442 
for 24 h, despite all three strains demonstrating susceptibility in a standard MIC test. 443 
For ATCC29213 there was no significant effect of dose (ANOVA, f2,21=0.2 p=0.8) or  444 
dosing interval (ANOVA, f2,21=1.9 p=0.2) on CFU/ml.  Although there was an overall 445 
significant effect of dose on CFU/ml for FQ128 (ANOVA, f2,21=5.8, p=0.01) and FQ142 446 
(ANOVA, f2,21=7.5, p= 0.004), post-hoc analysis showed this was not significant for 447 
0.25mg/l (FQ128, p=0.8 and FQ142, p=0.2) and a mean decrease in CFU/ml of 448 
>3log10 was not achieved for either strain at this concentration (Fig 6b).  Dosing interval 449 
was found to be significant for FQ128 (f 2,21=7.2, p=0.004) but not for FQ142 (f 2,21 450 
=0.03, p=0.97). The fact that the required bactericidal target was not reached for the 451 
control strain, ATCC29213, and that the response of the two clinical isolates varied, 452 
shows that standard MIC testing may not reliably predict clinical response to antibiotic 453 
regimes. There was no significant decrease in bacterial recovery between pre-dose 454 
and 24 h post dose when challenged with 0.25mg/l flucloxacillin and FQ142 showed 455 
a potential to grow under these conditions, suggesting sub-inhibitory flucloxacillin 456 
concentrations could lead to the development of resistance. Furthermore, although 457 
5mg/l flucloxacillin had a significant effect on CFU/ml for both clinical strains, it failed 458 
to cause a  mean decrease in FQ128 CFU/ml of >3log10, suggesting that some strains 459 
could tolerate clinically relevant concentrations even when antibiotic protein binding is 460 
accounted for. This was a very small sample set, and further investigation is 461 
warranted, but, it indicates that maintaining plasma concentrations well above the 462 
target of 4 x MIC maybe necessary for effective treatment of S. aureus infection in CF.  463 
 464 
Discussion  465 
 466 
Growth and localization of S. aureus in EPVL. There is an apparent contradiction 467 
between the usual pathology of S. aureus in human CF samples (non-invasive) and in 468 
standard laboratory models using cell culture or mouse lung infections. To address this 469 
gap between the clinical norm and standard lab models, we grew a biobank of clinical 470 
isolates in an ex vivo model of CF lung infection which carefully mimics human tissue 471 
structure and the chemistry of CF lung secretions. S. aureus grew with reasonable 472 
consistency, both associated with lung tissue, at the airway surface, and as bacterial 473 
aggregates in artificial sputum (ASM) around the tissue. S. aureus bioburden was 474 
maintained in EPVL over 7 days, although tissue-associated CFU numbers were 475 
diminished over this period and in general the bacteria showed a preference for growth 476 
as aggregates suspended in the ASM.  477 
 478 
Defined biofilm was not investigated in histological samples, although there was evidence 479 
of potential biofilm architecture and increased structure in bacterial populations for some 480 
samples by 7 days compared to 48 h. Interestingly, we have recently reported that 481 
Pseudomonas aeruginosa does demonstrate extensive biofilm growth in the EPVL that 482 
can be observed using the same histological staining techniques (40). This is consistent 483 
with the available clinical evidence where extensive biofilms have not been described for 484 
S. aureus in the CF lung (49), but small, biofilm-like aggregates are reported in the sputum 485 
and on the surface of airways (24, 25, 50, 51). Consistent with growth as aggregates in 486 
vivo, there is evidence that S. aureus switches off the global regulator agr in CF (48). 487 
 488 
We did not observe interstitial invasion by S. aureus. Generally, interstitial bacteria are 489 
rarely observed in biopsy samples from people with CF (even if significant interstitial 490 
inflammation is observed) and bacteria in the airways are confined in luminal mucus plugs 491 
or occasionally attached to defined foci of epithelial erosion; this lack of tissue invasion is 492 
consistent with the rarity of bacteremia in people with CF (24, 25, 52-57). CF lung disease 493 
thus presents as bronchiectasis with mucous plugging of small airways. In contrast, 494 
microscopy images presented in studies of murine pulmonary S. aureus infections 495 
typically show abscesses (a cavitating, pus-filled lesion within the tissue with a defined 496 
border: see Figure 2 in (31) and Figure 2 in (58), for examples) and lead to chronic 497 
pneumonia (59). Clearly, there are significant differences in S. aureus pathology in mouse 498 
models versus the highly specialised environment of CF airways as approximated by the 499 
ex vivo pig lung model.  500 
 501 
In light of this, it is significant that our results suggest preferential localisation of S. aureus 502 
in the ASM surrounding the tissue sections, as opposed to epithelial surface attachment, 503 
and we did not observe the appearance of abscess-like structures. S. aureus can cause 504 
lung abscess in humans – in fact it is one of the most common bacteria isolated from 505 
abscesses (60) – but abscesses are almost never observed in people with CF (56, 57). A 506 
specific Panton-Valentine Leukocidin positive strain of MRSA was associated with 507 
invasive, cavitating lung lesions in a CF centre in the USA in the mid 2000s (61), but this 508 
is unusual. Other than this specific outbreak, a literature search revealed only five cases 509 
of abscess among people with CF, only two of which were associated with S. aureus: one 510 
patient was co-colonized by P. aeruginosa and the other with P. denitrificans (34, 62). It 511 
should be noted that abscess formation is associated with the presence of neutrophils, 512 
our model uses post mortem tissue and, therefore, the effect of the host immune response 513 
is not observable. In addition tissue samples in our model are taken only from the bronchi 514 
wall and so may not capture abscess formation.  However, given the rarity of clinical 515 
evidence for invasive S. aureus infection in people with CF, induction of abscess formation 516 
may not be clinically important in a CF model. Clinical observations are consistent with a 517 
study in which mucus hypersecretion was induced in cultured primary nasal epithelia cells 518 
to better mimic conditions in the CF lung: mucus presence led to S. aureus cells moving 519 
away from the epithelial cell surface and growing in the mucus (25) – as observed in our 520 
model. 521 
 522 
Chronic infection phenotypes of S. aureus in EPVL. The tissue-associated 523 
subpopulation exhibited enhanced tolerance to flucloxacillin compared with standard 524 
susceptibility assay results. This is likely due to physiological cues from the lung 525 
environment and the appearance of a subpopulation of SCVs (11, 13, 63-65) but may also 526 
be influenced by the presence of biofilm structure matrix if it is present (which could 527 
usefully be explored in future work).  528 
 529 
Small colony variants emerged once S. aureus isolates were passaged through the EPVL. 530 
The phenotypic development of SCVs has been linked to chronic CF infections (63, 64). 531 
The impact of SCVs on virulence and persistence is difficult to study in vitro as they rapidly 532 
revert to normal colony morphology when attempts are made to culture them in vitro (51) 533 
and usually requires the creation of artificially generated, stable SCVs which may not fully 534 
represent those generated by the in vivo environment(66). Notwithstanding these 535 
limitations, studies have linked the SCV phenotype with attenuated virulence (67) and a 536 
dampened host cytokine response (68, 69) – both changes consistent with adoption of 537 
persistence strategy. The ability of the ex vivo lung model to cue SCV emergence is likely 538 
to be a significant strength of the model, permitting a rapid means to generate this 539 
phenotype and allowing more extensive future research into the effects of SCVs. It will be 540 
important, however, to tease apart the relative contributions of the presence of tissue and 541 
the presence of sub-inhibitory levels of ampicillin on SCV emergence. Since completing 542 
this work, we have begun a more extensive investigation of methods to reduce the 543 
presence of endogenous bacteria from the lung tissue, and we have found that expedited 544 
access to lungs after slaughter allows us to obtain tissue which requires less rigorous 545 
control measures. Future experiments using EVPL with different or no antibiotic 546 
supplementation will allow us to explore the impacts of tissue and antibiotic presence on 547 
microbial physiology. 548 
 549 
Population heterogenicity of S. aureus in vivo and in EVPL. The evidence outlined 550 
above is consistent with S. aureus growing as phenotypically heterogeneous populations 551 
in CF – comprising tissue-associated, biofilm-like aggregates and mucus-embedded 552 
aggregates, with potential presence of SCVs. Persistence, antibiotic tolerance, gene 553 
expression and ability to be cultured in vitro are likely to differ between these 554 
subpopulations, and understanding the differences within heterogenous populations could 555 
improve understanding of virulence mechanisms. If this is the case, the ex vivo pig lung 556 
model will be valuable in future study for the generation of heterogenous populations that 557 
are hard to reproduce in animal and traditional in vitro models.  558 
 559 
Strengths and limitations of the EVPL model. Our data reinforce the notion that host 560 
specific pathology is an important area of future study, with particular significance for S. 561 
aureus. Modelling S. aureus infection, in any tissue other than human biopsy, is likely to 562 
present differences and challenges. It is abundantly clear that both mouse and in vitro 563 
models fail to capture key features of pathology observed from human clinical data that 564 
are revealed by our EVPL model. Consequently, EVPL could fill an important gap in the 565 
toolkit for answering crucial questions about the microbiology and clinical impact of S. 566 
aureus in CF.  567 
 568 
There are, of course, some areas where the model could be optimised for future use. 569 
Primarily, variability in S. aureus bacterial load was considerable. We inoculated tissue 570 
sections from single colonies, and not a standardised broth culture, as preliminary work 571 
with P. aeruginosa in an earlier version of the model showed no significant variation in the 572 
number of cells inoculated from single colonies, or the cell numbers recorded at 48 h (39). 573 
Additionally, in CF there is unlikely to be a large burden of colonising bacteria (70).  Given 574 
the differences in the way that P. aeruginosa and S. aureus grow in the model, starting 575 
inoculum may be a more significant determinant of the growth and survival of S. aureus 576 
and standardising cell numbers could be important for future developments, for example 577 
assessing the impact of antimicrobial agents on viable bacterial burden. More broadly, 578 
better data on the variability in S. aureus aggregate size between foci of infection within 579 
CF lungs, and between patients, would be useful for understanding S. aureus pathology. 580 
In a study by Hirschhausen et al. (59), adaptive changes differed in patients infected with 581 
the same S. aureus clonal lineage, indicating that individual host factors had an impact on 582 
adaption. This is reminiscent of our results, which show significant variability between 583 
lungs taken from different pigs (Fig 2).  584 
 585 
We also stress, given the reported intraspecific phenotypic and genetic diversity of 586 
bacteria within and between people with CF, and given observed differences in the growth 587 
and localisation of a pair of isolates taken from stable infection and acute exacerbation 588 
(Fig 2 and 3-4), future work could usefully explore a larger collection of isolates in more 589 
depth. 590 
 591 
Conclusion.  592 
The ex vivo lung model is designed to maximise physicochemical similarity to chronically-593 
infected human CF airways. It is also high throughput and inexpensive, and because it 594 
uses post-consumer waste from the meat industry, it presents no ethical concerns (38). 595 
Our results from S. aureus infection of the ex vivo model reveal aspect of chronic CF 596 
pathology which are not captured by existing “gold standard” animal models: aggregation 597 
of bacterial cells associated with tissue but also (perhaps predominantly) in mucus; the 598 
development of SCVs; and an increase in antibiotic tolerance. The potential preferential 599 
binding of S. aureus to mucus, and lack of tissue invasion, is a phenomenon that may 600 
have clinical relevance, especially given current questions about the role of S. aureus as 601 
a CF pathogen and the consequences of trying to remove it. 602 
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Figures and Tables  838 
 839 
 840 
Figure 1. Recovery of Staphylococcus aureus following 48 H in the ex vivo pig lung model (EVPL). Each S. aureus isolate was 841 
inoculated into four replica bronchiolar sections of tissue (a single pair of lungs was used on each of 3 separate days). 842 
Uninfected tissue was used as a control. Samples were destructively sampled at 48 h post infection. S. aureus bacterial load 843 
was recovered on selective media (MSA) and is measured as total colony forming units per lung sample (Total CFU). Solid 844 
lines indicate median values and the limit of detection is shown as a dashed line, no colonies were observed on plates where 845 
data is at the limit of detection. USA300 is used as a representative control strain known to form biofilm. Clinical isolates 846 
were supplied by the Instituto de Investigación Sanitaria La Fe (Table S1, supplementary material) and numbers are 847 
designated as supplied.  Analysis of untransformed data by ANOVA showed statistically significant differences in the bacterial 848 
load attained by the different strains (F7,32 = 1.90, p = 0.02).  849 
 850 
Figure 2. Recovery of an exacerbation vs chronic CF isolate of Staphylococcus aureus in the ex vivo pig lung model EVPL. 851 
S. aureus isolates were inoculated into six replica bronchiolar sections of tissue from each of three independent pairs of 852 
lungs, and samples were destructively sampled at 48 h and 7 days post infection by removing the tissue section from 853 
surrounding ASM and bead beating to release adherent bacteria. S. aureus bacterial load was recovered on selective media 854 
(MSA) and measured as total colony forming units per tissue sample (CFU). Triplicate lungs are indicated by point shape, and 855 
lines represent mean values. The limit of detection is shown as a dashed line. Colony counts on MSA, for uninfected tissue, 856 
were not recorded above the detectable limit at 48 H demonstrating that there was no inherent S. aureus presence in the 857 
lung tissue prior to inoculation. USA300 is used as a representative control strain.  CF isolates supplied by the Instituto de 858 
Investigación Sanitaria La Fe and numbers are designated as supplied.  ANOVA conducted on log-transformed data revealed 859 
significant main effects of strain (F2,40 = 12.0, p < 0.001), lung (F2,40 = 6.03, p = 0.005) and day, and a significant interaction 860 
between lung and strain (F4,40 = 2.62, p = 0.049). There was no significant interaction between day and lung (F2,40 = 9.5, p = 861 
0.110) or day and strain (F2,40 = 1.73, p = 0.190).  862 
 863 
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 866 
 867 
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 870 
 871 
 872 
 873 
 874 
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 883 
Figure 5. Location of Staphylococcus aureus in ex vivo pig lung (EVPL) model 48 h and 7 days: CFU and proportion of CFU 884 
recovered from Artificial Sputum Media (ASM) vs. tissue. S. aureus isolates were inoculated into six replica bronchiolar 885 
sections of tissue from each of three independent pairs of lungs, and samples were destructively sampled at 48 h and 7 days 886 
post infection. Aliquots of the ASM surrounding each sampled piece of tissue were also assessed for bacterial load. USA300 887 
was used as representative control strain and an uninfected lung used as a negative control. Clinical isolates supplied by the 888 
Instituto de Investigación Sanitaria La Fe and numbers are designated as supplied. (a) S. aureus cell counts recovered on MSA 889 
agar from EPVL at 48 h and 7 days. Bacterial load measured as total colony forming units per tissue, surrounding ASM or 890 
total sample (CFU). Counts were taken from triplicate lungs, indicated by point shape. Non-parametric Kruskal Wallis tests 891 
were used to test for differences in the proportion of bacteria in the surrounding ASM at 48 h and 7 days. Increases in 892 
proportional growth in ASM were found for strains FQ128 (Chi-squared = 7.44, p =0.006, df = 1), FQ140 (Chi-squared = 11, p 893 
< 0.001, df = 1), FQ151 (Chi-squared = 7.1, p =0.008, df = 1) and USA300 (Chi-squared = 12.3, p < 0.001, df = 1).  FQ142 894 
showed no significant increase in ASM proportion (Chi-squared = 1.2, p = 0.22, df =1). (b) Proportion of total CFU recovered 895 
from tissue vs surrounding ASM at 48 h and 7 days. Line shows equal CFU in ASM and tissue, for reference. Minimum limit 896 
of detection 4.3 x 101. Linear models on log-log transformed data showed a significant correlation between growth 897 
associated with tissue and growth in surrounding ASM at both time points. (Full details of ANOVA results in Supplementary 898 
information, R2adj for models testing for effects of lung, strain, CFU lung and strain*CFU lung on CFU in ASM were 0.50 for 899 
48 h data and 0.36 for day 7 data.  900 
 901 
 902 
Figure 6 recovery of S. aureus clinical isolates from EPVL following flucloxacillin challenge. Each S. aureus isolate was 903 
inoculated into replica bronchiolar sections of tissue from the same pair of lungs, and incubated as previously described for 904 
48 h. Four replica samples were processed for counting of bacterial load, prior to antibiotic challenge (0 h, pre-dose). 905 
Remaining samples were moved to ASM containing either no antibiotic (  ), 0.25mg/l (  ) or 5mg/l (  )flucloxacillin and 906 
incubated for 4 or 24 h. Uninfected tissue pieces were used as control and processed as infected replica, no colonies were 907 
observed on recovery plates for uninfected controls. Lines represent mean bacterial load.  All isolates were classified as 908 
sensitive by standard antibiotic susceptibility testing (MIC <0.0625mg/l). Bactericidal activity, (>3log10 in CFU) was only 909 
observed against FQ142 when challenged with 5mg/l flucloxacillin for 24 h (Fig 6b, highlighted). Antibiotic dose had no 910 
significant effect for ATCC29213 (ANOVA, f2,21=0.2 p=0.8) for clinical strains there was an overall effect of dose: ANOVA, 911 
f2,21=5.8, p=0.01 and f2,21=7.5, p= 0.004 for FQ128 and FQ142 respectively. However post hoc analysis revealed there was no 912 
significance for either strain when exposed to 0.25mg/l flucloxacillin (FQ128, p=0.8 and FQ142, p=0.2).  913 
 914 
Supplementary data.  915 
Table S1.  Clinical Staphylococcus aureus strains isolated from sputum samples from individuals with CF. Samples and 916 
health data collected and donated by the Instituto de Investigación Sanitaria La Fe, Valencia.  Sample numbers are designated 917 
as supplied. 918 
 919 
Sample Patient 
Identifier 
Patient age at 
sampling  
Exacerbation Biofilm MRSA Other microorganisms isolated 
FQ16 51 21 No Strong No Pseudomonas aeruginosa, 
Aspergillus fumigatus 
FQ203 51 22 No Moderate No Pseudomonas aeruginosa, 
Burkholderia cepacia 
FQ22 21 17 No Moderate No no 
FQ91 80 7 No Weak No no 
FQ151 80 8 No Moderate Yes no 
FQ233 80 8 Mild Moderate Yes no 
FQ128 40 20 No Strong No Candida albicans 
FQ220 40 21 Yes Moderate No Candida albicans 
FQ140 99 8 No Moderate Yes Pseudomonas aeruginosa, 
Candida albicans 
FQ184 99 9 Severe Moderate Yes Pseudomonas aeruginosa 
FQ210 99 9 No None Yes Pseudomonas aeruginosa, 
Candida albicans, 
Haemophilus influenzae 
FQ142 25 13 No None No Candida albicans, 
Aspergillus fumigatus 
FQ228 25 14 Severe None No Candida albicans 
FQ118 70 14 No Strong No no 
FQ153 70 15 No Strong No Candida albicans 
FQ139 47 12 No Moderate No Aspergillus fumigatus 
FQ160 48 9 No Weak No no 
FQ224 48 10 No Weak No no 
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 937 
Table S2. Identification of Small Colony Variants (SCVs). Catalase and coagulase result and colony identity as confirmed by 938 
16S sequence. Samples were taken from lung homogenate or surrounding Artificial Sputum Media (ASM) at 7 days post 939 
inoculation and grown on MSA plates for 24 h at 37 °C in 5% CO2 and a further 48 h in ambient conditions. SCVs were selected 940 
as shown in Fig S1 and all confirmed with Staphylococcus specific primers prior to sequencing of the 16S-23S intergenic 941 
spacer.  942 
 943 
 944 
Strain originally 
inoculated 
Diameter of small 
colony identified (% 
WT) 
Coagulase Catalase 16S sequence 
identity 
USA300 27 + + S. aureus 
USA300 32 + + S. aureus 
FQ128 31 + + S. aureus 
FQ128 23 + + S. aureus 
FQ140 26 Weak + S. aureus 
FQ140 25 Weak + S. aureus 
FQ142 43 + + S. aureus 
FQ142 43 + + S. aureus 
FQ151 40 Weak + S. aureus 
FQ151 31 Weak + S. aureus 
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